CA2441538A1 - Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank - Google Patents

Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank Download PDF

Info

Publication number
CA2441538A1
CA2441538A1 CA002441538A CA2441538A CA2441538A1 CA 2441538 A1 CA2441538 A1 CA 2441538A1 CA 002441538 A CA002441538 A CA 002441538A CA 2441538 A CA2441538 A CA 2441538A CA 2441538 A1 CA2441538 A1 CA 2441538A1
Authority
CA
Canada
Prior art keywords
bone
composition
rankl
bone formation
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002441538A
Other languages
English (en)
Inventor
Jonathan Lam
F. Patrick Ross
Steven L. Teitelbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Barnes Hospital
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2441538A1 publication Critical patent/CA2441538A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

L'invention concerne un procédé d'amélioration de la formation osseuse, consistant à administrer une quantité efficace 1) d'un complexe oligomérique d'un ou plusieurs éléments parmi RANKL, une protéine de fusion RANKL ou un analogue, un dérivé ou un mimétique de cette dernière, 2) d'un composé ostéogénique capable d'améliorer l'activité d'une ou de plusieurs protéines intracellulaires dans des ostéoblastes ou des précurseurs d'ostéoblastes, ladite activité étant indicative d'une formation osseuse, ou 3) d'un composé ostéogénique capable d'inactiver une ou plusieurs phosphatases dans des ostéoblastes ou des précurseurs d'ostéoblastes, ladite inactivation étant indicative d'une formation osseuse. Le procédé peut également être utilisé pour traiter une maladie ou une condition se manifestant au moins en partie par la perte de masse osseuse, en administrant à un patient une composition pharmaceutique renfermant un complexe oligomérique ou un composé ostéogénique décrit ci-dessus.
CA002441538A 2001-03-22 2002-03-22 Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank Abandoned CA2441538A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US27785501P 2001-03-22 2001-03-22
US60/277,855 2001-03-22
US31116301P 2001-08-09 2001-08-09
US60/311,163 2001-08-09
US32923101P 2001-10-12 2001-10-12
US32887601P 2001-10-12 2001-10-12
US60/328,876 2001-10-12
US60/329,231 2001-10-12
US32939301P 2001-10-15 2001-10-15
US60/329,393 2001-10-15
PCT/US2002/009271 WO2002080955A1 (fr) 2001-03-22 2002-03-22 Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank

Publications (1)

Publication Number Publication Date
CA2441538A1 true CA2441538A1 (fr) 2002-10-17

Family

ID=27540621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002441538A Abandoned CA2441538A1 (fr) 2001-03-22 2002-03-22 Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank

Country Status (5)

Country Link
EP (1) EP1385532A4 (fr)
JP (1) JP2004526748A (fr)
CA (1) CA2441538A1 (fr)
EA (1) EA200301041A1 (fr)
WO (1) WO2002080955A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002443A (es) 2000-09-22 2004-12-06 Immunex Corp Ensayos de clasificacion para agonistas o antagonistas del activador receptor de nf-kb.
DK1732575T3 (da) * 2004-02-26 2011-03-28 Osteologix As Strontium indeholdende forbindelser til anvendelse til forebyggelse eller behandling af nekrotiske knoglesygdomme
EP1736482A1 (fr) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Ligand recombinant trimeric de 4-1BB
EP2020445B1 (fr) 2006-05-12 2013-01-02 Keio University Détection d'une maladie inflammatoire et composition destinée à la prévention ou au traitement d'une maladie inflammatoire
KR101235439B1 (ko) * 2006-10-11 2013-02-20 오리엔탈 이스트 컴파니 리미티드 가용형 ｒａｎｋｌ과 에피토프 태그의 융합 단백질을 포함하는 시약
WO2008044797A1 (fr) * 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
WO2008044379A1 (fr) * 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
EP2358352B1 (fr) * 2008-10-24 2018-08-29 Warsaw Orthopedic, Inc. Compositions et procédés pour favoriser la formation osseuse
CN114391506A (zh) * 2021-12-24 2022-04-26 华中科技大学同济医学院附属协和医院 一种恢复节律促进骨组织生长发育的运动方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69738841D1 (de) * 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
EP2009025B1 (fr) * 1998-05-14 2011-07-27 Immunex Corporation Procédé d'inhibition de l'activité des ostéoclastes
IL141588A0 (en) * 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands

Also Published As

Publication number Publication date
EA200301041A1 (ru) 2004-08-26
EP1385532A1 (fr) 2004-02-04
EP1385532A4 (fr) 2004-12-15
WO2002080955A1 (fr) 2002-10-17
JP2004526748A (ja) 2004-09-02

Similar Documents

Publication Publication Date Title
Missbach et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo
DK2120997T3 (en) MODULATION OF PRO-NEUROTROPHIN ACTIVITY
JP4469780B2 (ja) 骨成長および毛成長を刺激するためのプロテアソーム活性のインヒビター
Li et al. Role of endoplasmic reticulum stress in disuse osteoporosis
US20030013651A1 (en) Stimulation of osteogenesis using rank ligand fusion proteins
JP4248583B2 (ja) ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
JP6910078B2 (ja) Ｗｎｔ組成物および精製方法
CA2441538A1 (fr) Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank
Zhang et al. Calcitonin induces dephosphorylation of Pyk2 and phosphorylation of focal adhesion kinase in osteoclasts
Kawai et al. Prevention of skeletal muscle atrophy in vitro using anti-ubiquitination oligopeptide carried by atelocollagen
US9381245B2 (en) Methods for inhibiting osteolysis
Kang et al. A Vitronectin-Derived Peptide Restores Ovariectomy-Induced Bone Loss by Dual Regulation of Bone Remodeling
AU2002314726A1 (en) Stimulation of osteogenesis using rank ligand fusion proteins
US20020132759A1 (en) Remedies for diseases caused by insulin resistance
MXPA03008571A (es) Estimulacion de osteogenesis usando proteinas de fusion de ligando rank.
WO2003065972A2 (fr) Methodes de criblage de composes osteogenes
US20170360888A1 (en) Methods for treating inflammatory arthritis
JP2005514919A (ja) 骨抗吸収化合物
US20030082638A1 (en) Methods for screening osteogenic compounds
JP6105623B2 (ja) 核内因子κＢ活性化受容体（ＲＡＮＫ）をターゲティングするペプチドおよびそれらの適用
Yu et al. Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone
US7048919B2 (en) Osteoclast secreted chemokine and uses thereof
JP2004016074A (ja) Ａｍｐ活性化プロテインキナーゼ活性化剤
Jin The effect of developmentally regulated GTP-binding protein 2 on bone metabolism
WO2007066708A1 (fr) Induction de la formation de tissu dur sur la base d’un systeme de signalisation wnt5a/sfrp4

Legal Events

Date Code Title Description
FZDE Dead